Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6026
- Development stage
- Phase 2
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
SYS6026 is a therapeutic bivalent messenger RNA (mRNA) vaccine developed by CSPC Pharmaceutical Group. It targets high-grade squamous intraepithelial lesions (HSIL) associated with human papillomavirus (HPV) type 16 or 18. The vaccine consists of mRNA molecules encoding the E6 and E7 antigens of HPV types 16 and 18, delivered via a lipid nanoparticle (LNP) system. Upon administration, it induces the expression of these antigens in host cells, generating antigen-specific T cells that can eliminate HPV-infected cells and inhibit tumorigenesis. This approach aims to provide an effective non-surgical treatment for precancerous cervical lesions caused by HPV, addressing significant unmet clinical needs as there are currently no approved therapeutic vaccines for HPV-related lesions worldwide[2][6].
02
Targets
HPV16 E6 oncoproteinHPV18 E6 (HPV18 E6 protein)HPV16 E7 (Human papillomavirus 16 E7 protein)HPV18 E7
Beyond the preview
Go deeper on SYS6026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6026.